Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/21/2003CN1419565A Chimeric Prostate-homing peptides with pro-apoptotic activity
05/21/2003CN1419564A Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
05/21/2003CN1419563A Peptide derivative
05/21/2003CN1419442A Method of administering a medicinal aerosol formulation
05/21/2003CN1418964A Productive method of recombinant human liver regenerated enhanced factor and use in treating serious hepatopathy thereof
05/21/2003CN1418704A SOD nutriment capsule with high micro content
05/21/2003CN1418703A Nano particle feeding system for oral use
05/21/2003CN1418642A Process for prodn. of biological prepn. for antisenesence
05/21/2003CN1109106C Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them
05/21/2003CN1109102C Needleless syringe using supersonis gas flow for particle delivery
05/21/2003CN1109047C Amphiapathic moleculs as cholesterol and other lipid uptake inhibitors
05/21/2003CN1109046C Induction of cytotoxic T-lymphocyte responses
05/21/2003CN1109045C Process for preparation of virus-inactivated factor VIII-contg. fraction by chromatographic methods
05/21/2003CN1109043C 角质形成细胞生长因子－2 Keratinocyte growth factor-2
05/21/2003CN1108823C Excipient stabilization of polypeptides treated with organic solvents
05/21/2003CN1108821C Preparation of multiepitope-epitope vaccine
05/21/2003CN1108820C Preparation of epitope vaccine with single monoepitope or multiple monoepitope duplication
05/21/2003CN1108819C Preparation of dissociation-resisting epitope vaccine
05/21/2003CN1108818C Activated immune globulin
05/21/2003CN1108817C Thrombolytic medicine
05/21/2003CN1108816C Gluconokinase microemulsion and preparing process thereof
05/21/2003CN1108815C Compound alpha interferon lozenge and its preparing method
05/21/2003CN1108814C Process for manufacture of pharmaceutical composition containing polyethylene glycol protein conjugates
05/21/2003CN1108796C Use of anticancer material and production method of said anti-cancer material
05/21/2003CN1108795C Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or doner, or a nitric oxide inhibitor
05/20/2003US6566514 Antisense oligonucleotides for use in the treatment of tumors
05/20/2003US6566509 Compound for use as bactericide
05/20/2003US6566506 Useful in extending the in vivo circulating life of biologically active materials
05/20/2003US6566504 Adding to the protein solution a cyclodextrin in an amount sufficient to form a stable complex with the protein, lyophilizing, recovering lyophilized protein/cyclodextrin complex, heating complex to inactivate viruses
05/20/2003US6566503 Mammalian CX3C chemokine
05/20/2003US6566502 Diagnosing mammary gland or colon and rectum cancer; obtain tissue sample, monitor preferential gene expression, compare to control, evaluate adjustments in gene expression, diagnos for cancer
05/20/2003US6566500 Compositions and methods for modifying toxic effects of proteinaceous compounds
05/20/2003US6566499 Adipocyte-specific protein homologs
05/20/2003US6566498 Proteins for use in the treatment of thrombosis and tumor metastisis
05/20/2003US6566494 Support material for solid phase organic synthesis
05/20/2003US6566493 Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
05/20/2003US6566491 Cyclopeptide derivatives
05/20/2003US6566407 Administering to a patient suffering from kidney stone calcium oxalate deposit) therapeutically effective amount of one or more crosslinked aliphatic amine polymers such as polyallylamine, polydiallylamine or polyvinylamine
05/20/2003US6566377 Have utility as, inter alia, hypoglycemic, and anti-obesity agents.
05/20/2003US6566365 Method for the treatment of Flaviviridea viral infection using nucleoside analogues
05/20/2003US6566354 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
05/20/2003US6566345 Polyacid/polyalkylene oxide foams and gels and methods for their delivery
05/20/2003US6566343 High affinity nucleic acid ligands of complement system proteins
05/20/2003US6566342 Genetic engineering
05/20/2003US6566340 Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use
05/20/2003US6566338 Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal
05/20/2003US6566337 Compounds with growth hormone releasing properties
05/20/2003US6566335 Administering a peptide derivative for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood
05/20/2003US6566334 Short amphipathic peptides with activity against bacteria and intracellular pathogens
05/20/2003US6566333 Osteoclast secreted chemokine and uses thereof
05/20/2003US6566332 OBG3 globular head and uses thereof for decreasing body mass
05/20/2003US6566331 Treatment of collagen related diseases
05/20/2003US6566330 Positively charged non-natural amino acids, methods of making and using thereof in peptides
05/20/2003US6566329 Single lyophilization of an aqueous slurry of an amorphous human growth hormone isoprecipitate, the slurry having a the slurry having a pH of from about 4.7 to 5.0
05/20/2003US6566328 Administering to the patient a therapeutically effective amount of a polypeptide for therapy of patient in need of agonist effect of human growth hormone
05/20/2003US6566327 Histogranin peptides and their analgesic use
05/20/2003US6566326 Chemically modified hemoglobin for burn shock resuscitation
05/20/2003US6566325 And isolated nucleic acids containing coding regions of genes encoding such proteins; for use in gene therapy treatment of cancer, autoimmune diseases, viral diseases
05/20/2003US6566135 Antisense modulation of caspase 6 expression
05/20/2003US6566133 Antisense inhibition of dual specific phosphatase 9 expression
05/20/2003US6566132 Antisense modulation of Interferon gamma receptor 1 expression
05/20/2003US6566131 Antisense modulation of Smad6 expression
05/20/2003US6566127 Enzymatic nucleic acid for use in the treatment of tumors, vision defects, arthritis and skin disorders
05/20/2003US6566116 Enzymatic polypeptide for use in the treatment of diabetic nephropathy, glomerulonephritis, fibrosis, liver and kidney disorders, osteoporosis and lung disorders
05/20/2003US6566108 Genetically engineered cell for use in the expression of heterologous proteins and particles
05/20/2003US6566104 Enzymatic polypeptide for use in the diagnosis and treatment of cancer
05/20/2003US6566099 Nucleotide sequences coding polypeptide for use in the treatment of lysosomal storage disease
05/20/2003US6566098 DNA encoding truncated hepatocyte growth factor variants
05/20/2003US6566097 Polypeptide for use in the treatment of mammalian viral diseases
05/20/2003US6566094 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
05/20/2003US6566093 Alphavirus cDNA vectors
05/20/2003US6566092 Nucleotide sequences coding polypeptide for use in the treatment nervous system disorders
05/20/2003US6566091 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
05/20/2003US6566087 Detection of preferential enzymatic polypeptide; obtain sample containing enzymatic polypeptide, expose to modulator, monitor binding, detect adjustment in enzyme activity
05/20/2003US6566084 Detecting hydrolysis of cocaine compound; obtain cocaine mixture, incubate with antibody, monitor generation of benzoic zacid
05/20/2003US6566082 T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions
05/20/2003US6566080 Assay for and uses of peptide hormone receptor agonists
05/20/2003US6566078 36P6D5: secreted tumor antigen
05/20/2003US6566074 Modulation of cell attachement; obtain cells, administering antibody that binds to a syndecan domain on cell surface, monitor cell attachment, evaluate cell for cancer
05/20/2003US6566072 Diagnosing mammary gland cancer in humans; obtain tissue sample, recover proteins, incubate with antibody, detect presence bound antibody, amplified presence of boubd antibody indicates cancer
05/20/2003US6566070 Detecting preferential protein biosynthesis; label nucleotide sequences, mix with translation system, incubate, detct signal from protein
05/20/2003US6566066 Aquaporin-8 variant
05/20/2003US6566065 Diagnosing schizophrenia in humans; obtain sample, analyze the methylenetetrahydrofolate reductase nucleic acid expression in sample, genotype sample, presence of mutation indicates schizophrenia
05/20/2003US6566063 Diagnosing cancer in cells; obtain cells, monitor expression of gland-specific transcription factor, compare to control, evaluate for cancer
05/20/2003US6566056 Diagnosing cancer in humans; obtain genetically engineered cell, monitor gene expression adjustment and phenotypes, compare to control, evaluate for cancer
05/20/2003US6565874 Polymeric delivery formulations of leuprolide with improved efficacy
05/20/2003US6565870 In situ administering neurotoxin
05/20/2003US6565869 Administering genetic engineered polypeptide
05/20/2003US6565858 Human ADAMTS-1 protein and pharmaceutical composition
05/20/2003US6565857 Coding human leukocyte antigen; anticancer, antitumor agent
05/20/2003US6565856 Polypeptide; inducting immunology response
05/20/2003US6565854 Killing microorganisms, especially human pathogens; use in would dressings; animal feeds; vaccines
05/20/2003US6565848 Cadherin-like asymmetry protein-1, and methods for its use
05/20/2003US6565847 Thermogenic weight management composition
05/20/2003US6565844 Protein production and protein delivery
05/20/2003US6565843 Protein-induced tissue morphogenesis
05/20/2003US6565842 Crosslinking gel
05/20/2003US6565841 Pulmonary administration of granulocyte colony stimulating factor
05/20/2003US6565833 Medicinal aerosol formulation
05/20/2003US6565831 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
1 ... 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 ... 3163